Prior to joining Volastra, Linda worked in oncology clinical development as director of clinical research at I-Mab Biopharma in early phase development for all their immuno-oncology assets in solid and hematological tumors. Along with clinical science responsibilities, Linda also worked cross functionally assisting with business development due diligence for in-licensing assets.

Prior to industry, Linda worked at Dana Farber Cancer Institute and Yale New Haven Hospital. At Yale, Linda was a clinical research pharmacist with the Early Drug Development Program supporting all oncology phase 1 studies. Linda has assumed leadership and active participant roles in various national professional organizations including American Society of Clinical Oncology (ASCO), Southwest Oncology Group (SWOG) and American Society of Health-Systems Pharmacists (ASHP). Linda was appointed SWOG Chair of the Drug Information Subcommittee under the Pharmaceutical Sciences group, where she worked with SWOG investigators on drug-related issues during protocol development and implementation processes. Linda earned her Doctor of Pharmacy (PharmD) degree from the Massachusetts College of Pharmacy and Health Sciences.